{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:31:12Z","timestamp":1792161072310,"version":"4.4.0"},"reference-count":45,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Interest in psychedelic therapies for adults is rapidly growing, with substances like 3,4-methylenedioxymethamphetamine for posttraumatic stress disorder, psilocybin for treatment-resistant depression, and lysergic acid diethylamide for generalized anxiety disorder showing promise. However, research on these therapies in children and adolescents is limited, with no recent trials. Despite this lack of scientific exploration, adolescents may still experiment with these substances for both recreational and therapeutic purposes as accessibility continues to increase. This raises significant concerns, as adolescents are a vulnerable population requiring heightened caution and safety measures. Therefore, we advocate for structured, safe, and well-controlled exploration of psychedelic therapies in adolescents.<\/jats:p>","DOI":"10.1089\/cap.2024.0082","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T11:30:55Z","timestamp":1736163055000},"page":"118-125","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor"],"prefix":"10.1177","volume":"35","author":[{"given":"Isabella","family":"Sutherland","sequence":"first","affiliation":[{"name":"University of Vermont Larner College of Medicine, Burlington, Vermont, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Fen","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA."},{"name":"Department of Molecular Pharmacology and Experimental Therapeutics, Rochester, MN, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6843-6503","authenticated-orcid":false,"given":"Paul E.","family":"Croarkin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-022-06123-7"},{"key":"e_1_3_3_3_1","unstructured":"Agency for Healthcare Research and Quality. 2022 National healthcare quality and disparities report. U.S. Department of Health and Human Services. Available from: https:\/\/www.ahrq.gov\/research\/findings\/nhqrdr\/nhqdr22\/index.html"},{"key":"e_1_3_3_4_1","unstructured":"Alpert JE McDonald WM Nemeroff CB et al. Position statement on the use of psychedelic and empathogenic agents for mental health conditions. American Psychiatric Association 2022. Available at: https:\/\/www.psychiatry.org\/getattachment\/d5c13619-ca1f-491f-a7a8-b7141c800904\/Position-Use-of-Psychedelic-Empathogenic-Agents. pdf"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-021-00465-5"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00859"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221116926"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994"},{"key":"e_1_3_3_9_1","unstructured":"Compass Pathways. COMPASS pathways receives FDA breakthrough therapy designation. 2018. Available from: https:\/\/compasspathways.com\/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression\/ [October 23 August 24 2024]"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.42210"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0030"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.13202"},{"key":"e_1_3_3_13_1","unstructured":"FDA grants Breakthrough Therapy Designation to Usona Institute\u2019s psilocybin program for major depressive disorder. Usona Institute 2019. Available from: https:\/\/www.usonainstitute.org\/updates\/fda-grants-breakthrough-therapy-designation-to-usona-institutes-psilocybin-program-for-major-depressive-disorder"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00943"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2010.11.030"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211073759"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01639-6"},{"key":"e_1_3_3_19_1","unstructured":"Jeffrey J. Study Details | MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents | ClinicalTrials.Gov. n.d. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06353282?intr=mdma&aggFilters=ages:child status:not%20rec&rank=1 [Last accessed: July28 2024]."},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05548-2"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2016.03.064"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.1603"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.160"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.09.005"},{"key":"e_1_3_3_25_1","unstructured":"Lykos Therapeutics Announces Complete Response Letter for Midomafetamine Capsules for PTSD. n.d. Available from: https:\/\/news.lykospbc.com\/2024-08-09-Lykos-Therapeutics-Announces-Complete-Response-Letter-for-Midomafetamine-Capsules-for-PTSD [Last accessed: August10 2024]."},{"key":"e_1_3_3_26_1","unstructured":"Major Depression - National Institute of Mental Health (NIMH). n.d. Available from: https:\/\/www-nimh-nih-gov.ezp.med.uvm.edu\/health\/statistics\/major-depression [Last accessed: July13 2024]."},{"key":"e_1_3_3_27_1","unstructured":"MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder. MindMed 2024. Available from: https:\/\/ir.mindmed.co\/news-events\/press-releases\/detail\/137\/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02565-4"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110378371"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30135-4"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112464827"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118806297"},{"key":"e_1_3_3_33_1","unstructured":"Psilocybin for Major Depressive Disorder (MDD) (uAspire). ClinicalTrials.gov identifier: NCT06308653. August 20 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06308653 [Last accessed: August30 2024]."},{"key":"e_1_3_3_34_1","unstructured":"Psychopharmacologic Drugs Advisory Committee Meeting (PDAC). Food and Drug Administration Center for Drug Evaluation and Research; June 4 2024. Available from: https:\/\/www.fda.gov\/media\/180703\/download [Last accessed: August10 2024]."},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.14530"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19010035"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.040"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1977.10472034"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.12.040"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2013.7"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.0047"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2767"},{"key":"e_1_3_3_43_1","unstructured":"Usona Institute. Study Details | Psilocybin for Major Depressive Disorder (MDD) | ClinicalTrials.Gov. n.d. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06308653?term=NCT06308653&ra= [Last accessed: August24 2024]."},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101809"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3672"},{"key":"e_1_3_3_46_1","unstructured":"2022 National Healthcare Quality and Disparities Report. Rockville MD: Agency for Healthcare Research and Quality; October 2022. AHRQ Pub. No. 22(23)-0030."}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2024.0082","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2024.0082","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2024.0082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:57:09Z","timestamp":1777388229000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2024.0082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1089\/cap.2024.0082"],"URL":"https:\/\/doi.org\/10.1089\/cap.2024.0082","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}